Epistem plc, a UK biotechnology and contract research company, will present results from their latest plucked hair biomarker study at the ASCO-NCI-EORTC Meeting on Molecular Markers in Cancer, Hollywood FL, United States on Friday 31st October 2008.
Epistem to Present Plucked Hair Biomarker Data at ASCO-NCI-EORTC Meeting
MANCHESTER, UNITED KINGDOM --(Marketwire-October 27, 2008) - Epistem plc (LSE: EHP), the UK biotechnology and contract research company, will present results from their latest plucked hair biomarker study at the ASCO-NCI-EORTC Meeting on Molecular Markers in Cancer, Hollywood FL, United States on Friday 31st October 2008. Dr Ged Brady will present data to show that cell cycle genes, previously identified in breast tumour tissue and linked to clinical outcome in breast cancer patients, are also differentially expressed in single intact and dissected plucked hairs from healthy normal volunteers.
The study demonstrates the viability of monitoring gene expression in single human hairs to identify expression profiles relevant to tumour biology. Using a minimally invasive approach to obtain sensitive and reproducible data, the results support the case that plucked hairs are a suitable surrogate tissue for biomarker identification and analysis in clinical oncology trials.
The abstract will be available on request following the presentation (poster session C 5:30 – 7:00 pm).
For further information on the Company, please visit www.epistem.co.uk or contact:
Dr. Danielle Hargreaves +44 (0)161 606 7258
Public Relations +44 (0) 7920 815603
Epistem plc. info@epistem.co.uk
Mike Wort / Anna Dunphy +44 (0) 207 861 3838
Financial PR/IR
De Facto Communications
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Phase III PROMINENT Trial Initiated to Evaluate Felzartamab for Primary Membranous Nephropathy
June 30th 2025The global Phase III PROMINENT trial has begun dosing patients to evaluate felzartamab in treating primary membranous nephropathy, a serious autoimmune kidney disorder with no FDA-approved therapies.